Literature DB >> 24931594

Dynamic contrast-enhanced magnetic resonance imaging: applications in oncology.

Q Q Teo1, C H Thng2, T S Koh2, Q S Ng3.   

Abstract

Dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) allows functional characterisation of tissue perfusion characteristics and acts as a biomarker for tumour angiogenesis. It involves serial acquisition of MRI images before and after injection of contrast, as such, tissue perfusion and permeability can be assessed based on the signal enhancement kinetics. The ability to evaluate whole tumour volumes in a non-invasive manner makes DCE MRI especially attractive for potential oncological applications. Here we provide an overview of the current research involving DCE MRI as a biomarker for the diagnosis and characterisation of malignancies, prediction of the therapeutic response and survival outcomes, as well as radiation therapy planning.
Copyright © 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; dynamic contrast-enhanced imaging; functional imaging; magnetic resonance imaging; perfusion imaging

Mesh:

Substances:

Year:  2014        PMID: 24931594     DOI: 10.1016/j.clon.2014.05.014

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  7 in total

1.  Impact of uncertainty in longitudinal T1 measurements on quantification of dynamic contrast-enhanced MRI.

Authors:  Madhava P Aryal; Thomas L Chenevert; Yue Cao
Journal:  NMR Biomed       Date:  2016-01-21       Impact factor: 4.044

2.  Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model.

Authors:  Hyunki Kim; Sharon Samuel; John W Totenhagen; Marie Warren; Jeffrey C Sellers; Donald J Buchsbaum
Journal:  J Vis Exp       Date:  2015-04-18       Impact factor: 1.355

3.  Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma.

Authors:  Jian-Feng Yang; Zhen-Hua Zhao; Yu Zhang; Li Zhao; Li-Ming Yang; Min-Ming Zhang; Bo-Yin Wang; Ting Wang; Bao-Chun Lu
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

4.  Feasibility of free-breathing dynamic contrast-enhanced MRI of gastric cancer using a golden-angle radial stack-of-stars VIBE sequence: comparison with the conventional contrast-enhanced breath-hold 3D VIBE sequence.

Authors:  Huan-Huan Li; Hui Zhu; Lei Yue; Yi Fu; Robert Grimm; Alto Stemmer; Cai-Xia Fu; Wei-Jun Peng
Journal:  Eur Radiol       Date:  2017-12-19       Impact factor: 5.315

5.  The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma.

Authors:  Xiang Xu; Jiadi Xu; Linda Knutsson; Jing Liu; Huanling Liu; Yuguo Li; Bachchu Lal; John Laterra; Dmitri Artemov; Guanshu Liu; Peter C M van Zijl; Kannie W Y Chan
Journal:  Magn Reson Med       Date:  2019-02-22       Impact factor: 4.668

6.  A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma.

Authors:  Michelle M Kim; Yilun Sun; Madhava P Aryal; Hemant A Parmar; Morand Piert; Benjamin Rosen; Charles S Mayo; James M Balter; Matthew Schipper; Nicolette Gabel; Emily M Briceño; Daekeun You; Jason Heth; Wajd Al-Holou; Yoshie Umemura; Denise Leung; Larry Junck; Daniel R Wahl; Theodore S Lawrence; Yue Cao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-01-29       Impact factor: 8.013

7.  An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors.

Authors:  Anastassia Karageorgis; Sandrine Dufort; Lucie Sancey; Maxime Henry; Samuli Hirsjärvi; Catherine Passirani; Jean-Pierre Benoit; Julien Gravier; Isabelle Texier; Olivier Montigon; Mériem Benmerad; Valérie Siroux; Emmanuel L Barbier; Jean-Luc Coll
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.